MF

Michaela Fontenay

A( Assistance Publique—Hôpitaux De Paris (Aphp): 5 patents #28 of 877Top 4%
IR Institut Gustave Roussy: 4 patents #13 of 201Top 7%
UD Universite De Paris Descartes: 4 patents #15 of 364Top 5%
CB Centre Henri Becquerel: 4 patents #1 of 11Top 10%
UP Université Paris-Sud: 3 patents #10 of 307Top 4%
U6 Universite Pierre Et Marie Curie (Paris 6): 2 patents #51 of 554Top 10%
UC Université Pierre Et Marie Curie: 2 patents #14 of 215Top 7%
MO Moraine: 1 patents #25 of 84Top 30%
CN CNRS: 1 patents #3,857 of 11,908Top 35%
AA Apogenix Ag: 1 patents #10 of 16Top 65%
UC Université Paris Cité: 1 patents #123 of 608Top 25%
Overall (All Time): #826,746 of 4,157,543Top 20%
6
Patents All Time

Issued Patents All Time

Showing 1–6 of 6 patents

Patent #TitleCo-InventorsDate
11203788 TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms Franck Viguie, Olivier Bernard, Christian Bastard, Francois Delhommeau, William Vainchenker 2021-12-21
10662482 TET2 as a diagnostic and prognostic marker in hematopoietic neoplasms Franck Viguie, Olivier Bernard, Christian Bastard, Francois Delhommeau, William Vainchenker 2020-05-26
9675590 Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromes Olivier Hermine, Flavia GUILLEM, Jean-Benoit Arlet, Genevève Courtois 2017-06-13
9540431 Inhibitors of the CD95 signaling pathway for treatment of MDS Harald Fricke, Claudia KUNZ 2017-01-10
9389233 TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms Franck Viguie, Olivier Bernard, Christian Bastard, Francois Delhommeau, William Vainchenker 2016-07-12
9297046 TET2 as a new diagnostic and pronostic marker in hematopoietic neoplasms Franck Viguie, Olivier Bernard, Christian Bastard, Francois Delhommeau, William Vainchenker 2016-03-29